The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
Open accessAbstract
Tumor-specific CD8+ T cells can potentially be activated by two distinct mechanisms of major histocompatibility complex class I–restricted antigen presentation as follows: direct presentation by tumor cells themselves or indirect presentation by professional antigen-presenting cells (APCs). However, controversy still exists as to whether indirect presentation (the cross-priming mechanism) can contribute to effective in vivo priming of tumor-specific CD8+ T cells that are capable of eradicating cancer in patients. A clinical trial of vaccination with granulocyte macrophage–colony stimulating factor–transduced pancreatic cancer lines was designed to test whether cross-presentation by locally recruited APCs can activate pancreatic tumor-specific CD8+ T cells. Previously, we reported postvaccination delayed-type hypersensitivity (DTH) responses to autologous tumor in 3 out of 14 treated patients. Mesothelin is an antigen demonstrated previously by gene expression profiling to be up-regulated in most pancreatic cancers. We report here the consistent induction of CD8+ T cell responses to multiple HLA-A2, A3, and A24-restricted mesothelin epitopes exclusively in the three patients with vaccine-induced DTH responses. Importantly, neither of the vaccinating pancreatic cancer cell lines expressed HLA-A2, A3, or A24. These results provide the first direct evidence that CD8 T cell responses can be generated via cross-presentation by an immunotherapy approach designed to recruit APCs to the vaccination site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 2×
“cording to the following published sequences: M1 peptide (58–66) GILGFVFTL, derived from influenza matrix protein (29); mesothelin A2 (20–28) peptide SLLFLLFSL; mesothelin A2 (530–538) peptide VLPLTVAEV, identified using the available databases; and HIV-gag A2 peptide SLYNTVATL (75–83) (30), which contains an HLA-A2 b…”
MethodDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Self-citationDendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
Albert, M. L., Sauter, B., & Bhardwaj, N. (1998) · Nature · doi:10.1038/32183 · Cited by 2,349
SYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,314
Jung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Parker, K. C., Bednarek, M. A., & Coligan, J. E. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.1.163 · Cited by 1,370
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Antigen Recognition by Class I-Restricted T Lymphocytes
Townsend, A., & Bodmer, H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.003125 · Cited by 1,198
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Self-citationA Phagosome-to-Cytosol Pathway for Exogenous Antigens Presented on MHC Class I Molecules
Kovacsovics-Bankowski, M., & Rock, K. L. (1995) · Science · doi:10.1126/science.7809629 · Cited by 884
Cross-Presentation, Dendritic Cells, Tolerance and Immunity
Heath, W. R., & Carbone, F. R. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.47 · Cited by 882
Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.145 · Cited by 600
Self-citationSigal, L. J., Crotty, S., Andino, R., & Rock, K. L. (1999) · Nature · doi:10.1038/18038 · Cited by 578
Argani, P., Iacobuzio–Donahue, C. A., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E. M., Yeo, C. J., et al. (2001) · PubMed · Cited by 574
Self-citationSoiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13141 · Cited by 571
Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
Salter, R. D., Howell, D. N., & Cresswell, P. (1985) · Immunogenetics · doi:10.1007/bf00375376 · Cited by 566
Measurement of Delayed Skin-Test Responses
Sokal, J. E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197509042931013 · Cited by 500
Cross-presentation in viral immunity and self-tolerance
Heath, W. R., & Carbone, F. R. (2001) · Nature Reviews Immunology · doi:10.1038/35100512 · Cited by 480
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. J., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., et al. (1998) · The Journal of Urology · doi:10.1097/00005392-199802001-00032 · Cited by 410
Self-citationSkipper, J. C., Hendrickson, R. C., Gulden, P. H., Brichard, V, Van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Boon, T., et al. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.527 · Cited by 405
Self-citationDendritic cell maturation is required for the cross-tolerization of CD8+ T cells
Albert, M. L., Jegathesan, M., & Darnell, R. B. (2001) · Nature Immunology · doi:10.1038/ni722 · Cited by 402
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
Quantification of antigen specific CD8+ T cells using an ELISPOT assay
Miyahira, Y., Murata, K., Rodriguez, D., Rodriguez, J. R., Esteban, M., Rodrigues, M. M., & Zavala, F. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)00327-s · Cited by 359
Argani, P., Rosty, C., Reiter, R. E., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Ryu, B., Skinner, H. G., Goggins, M., Jaffee, E. M., et al. (2001) · PubMed · Cited by 313
Self-citationTargeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
Falo, L. D., Kovacsovics-Bankowski, M., Thompson, K., & Rock, K. L. (1995) · Nature Medicine · doi:10.1038/nm0795-649 · Cited by 289
Processing of engulfed apoptotic bodies yields T cell epitopes
Bellone, M., Iezzi, G., Rovere, P., Galati, G., Ronchetti, A., Protti, M. P., Davoust, J., Rugarli, C., & Manfredi, A. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5391 · Cited by 261
Berd, D., Maguire, H. C., Jr., & Mastrangelo, M. J. (1986) · PubMed · Cited by 251
Nouri-Shirazi, M., Banchereau, J., Bell, D., Burkeholder, S., Kraus, E. T., Davoust, J., & Palucka, K. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.3797 · Cited by 242
Schuurhuis, D. H., Ioan-Facsinay, A., Nagelkerken, B., van Schip, J. J., Sedlik, C., Melief, C. J. M., Verbeek, J. S., & Ossendorp, F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2240 · Cited by 238
In Vivo Cross-Priming of MHC Class I–Restricted Antigens Requires the TAP Transporter
Huang, A. Y. C., Bruce, A. T., Pardoll, D. M., & Levitsky, H. I. (1996) · Immunity · doi:10.1016/s1074-7613(00)80248-4 · Cited by 224
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo
Scheffer, S. R., Nave, H., Korangy, F., Schlote, K., Pabst, R., Jaffee, E. M., Manns, M. P., & Greten, T. F. (2003) · International Journal of Cancer · doi:10.1002/ijc.10777 · Cited by 201
Self-citationDhodapkar, M. V., Krasovsky, J., & Olson, K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202491499 · Cited by 170
A sensitive ELISPOT assay to detect low-frequency human T lymphocytes
McCutcheon, M., Wehner, N., Wensky, A., Kushner, M., Doan, S., Hsiao, L., Calabresi, P., Ha, T., Tran, T. V., Tate, K. M., et al. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00182-8 · Cited by 158
Ryu, B., Jones, J., Blades, N. J., Parmigiani, G., Hollingsworth, M. A., Hruban, R. H., & Kern, S. E. (2002) · PubMed · Cited by 156
Self-citationMoulton, H. M., Yoshihara, P., Mason, D. H., Iversen, P. L., & Triozzi, P. L. (2002) · PubMed · Cited by 147
DiBrino, M., Tsuchida, T., Turner, R. V., Parker, K. C., Coligan, J. E., & Biddison, W. E. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.11.5930 · Cited by 139
Sigal, L. J., & Rock, K. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.8.1143 · Cited by 135
On cross-priming of MHC class I-specific CTL: rule or exception?
Zinkernagel, R. M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200209)32:9<2385::aid-immu2385>3.0.co;2-v · Cited by 134
Greten, T. F., & Jaffee, E. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1047 · Cited by 130
Self-citationIntracellular transport of class I MHC molecules in antigen processing mutant cell lines.
Anderson, K. S., Alexander, J., Wei, M. L., & Cresswell, P. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.7.3407 · Cited by 113
Disis, M. L., Schiffman, K., Gooley, T. A., McNeel, D. G., Rinn, K. J., & Knutson, K. L. (2000) · PubMed · Cited by 112
Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells.
Oren, M. E., & Herberman, R. B. (1971) · PubMed Central · Cited by 108
Ohashi, P. S., & DeFranco, A. L. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00406-5 · Cited by 107
McCune, C. S., O’Donnell, R., Marquis, D. M., et al. (1990) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741726 · Cited by 103
Hoover, H. C., Surdyke, M. G., Dangel, R. B., et al. (1984) · PubMed · Cited by 96
Ercolini, A. M., Machiels, J., Chen, Y. C., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.8.4273 · Cited by 95
Self-citationFactors Affecting the Efficiency of CD8+ T Cell Cross-Priming with Exogenous Antigens
Maecker, H. T., Ghanekar, S., Suni, M. A., He, X.-S., Picker, L. J., & Maino, V. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7268 · Cited by 90
Multiple Antigen-Specific Processing Pathways for Activating Naive CD8+ T Cells In Vivo
Norbury, C. C., Princiotta, M. F., Bačík, I., Brutkiewicz, R. R., Wood, P., Elliott, T. J., Bennink, J. R., & Yewdell, J. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.7.4355 · Cited by 89
Dai, J., Liu, B., Caudill, M. M., Zheng, H., Qiao, Y., Podack, E. R., & Li, Z. (2003) · PubMed · Cited by 82
A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.
Pascolo, S., Schirle, M., Gückel, B., Dumrese, T., Stumm, S., Kayser, S., Moris, A., Wallwiener, D. R., Rammensee, H., & Stevanović, S. (2001) · PubMed · Cited by 80
Redundancy of Direct Priming and Cross-Priming in Tumor-Specific CD8+ T Cell Responses
Wolkers, M. C., Stoetter, G., Vyth‐Dreese, F. A., & Schumacher, T. N. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.3577 · Cited by 75
Yu, P., Spiotto, M. T., Lee, Y., Schreiber, H. W., & Fu, Y. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021804 · Cited by 75
Lu, J., & Celis, E. (2000) · PubMed · Cited by 67
DiFronzo, L. A., Gupta, R. K., Essner, R., Foshag, L. J., O'Day, S. J., Wanek, L. A., Stern, S. L., & Morton, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.065 · Cited by 58
Propato, A., Schiaffella, E., Vicenzi, E., Francavilla, V., Baloni, L., Paroli, M., Finocchi, L., Tanigaki, N., Ghezzi, S., Ferrara, R., et al. (2001) · Human Immunology · doi:10.1016/s0198-8859(01)00245-2 · Cited by 55
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction
Hodi, F. S., Schmollinger, J. C., Soiffer, R. J., Salgia, R., Lynch, T. J., Ritz, J., Alyea, E. P., Yang, J., Neuberg, D. S., Mihm, M. C., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102025999 · Cited by 49
Cited by
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Self-citationCarpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Metadata
- Authors
- Thomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y.-C., Huang, L.-Q., Laheru, D. A., Goggins, M., Hruban, R. H., & Jaffee, E. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-08-02
- Volume
- 200
- Issue
- 3
- Pages
- 297-306
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2106775454
- Cited by
- 347
- References
- 57
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.